A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Clinical Cancer Research|2019Cited by 52
Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent MechanismsMari C. Vázquez‐Borrego, Raúl M. Luque, Antonio C. Fuentes-Fayos et al.|The Journal of Clinical Endocrinology & Metabolism|2019Cited by 36
Association between radiological parameters and clinical and molecular characteristics in human somatotropinomasMaría Rosa Alhambra-Expósito, Raúl M. Luque, Alejandro Ibáñez‐Costa et al.|Scientific Reports|2018Cited by 28
Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs ResistanceAntonio C. Fuentes-Fayos, Raúl M. Luque, Miguel E. G-García et al.|International Journal of Molecular Sciences|2022Cited by 9
Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanismsAura D. Herrera‐Martínez, Raúl M. Luque, Antonio C. Fuentes-Fayos et al.|Endocrine Abstracts|2019Cited by 1